Neurol. praxi. 2024;25(3):224-229 | DOI: 10.36290/neu.2024.025

New treatment options for Neuromyelitis optica spectrum disorders (NMOSD)

prof. MUDr. Jarmila Szilasiová, PhD.
Neurologická klinika UPJŠ LF a UN L. Pasteura, Košice

The article provides an overview of the current state of knowledge about neuromyelitis optica spectrum disorder (NMOSD) immunotherapy. Therapy focuses on the relapses that determine disability in NMOSD. Autoantibodies against aquaporin 4 (AQP4-IgG) are a diagnostic biomarker of the disease and have an important role in the pathogenesis of damage to astrocytes. Recent advances in the understanding of NMOSD have led to the development of new therapies and validation of their effectiveness in randomized controlled trials. New immunotherapies have been approved for patients with positive AQP4-igG antibodies, with the potential to reduce the number of relapses, namely eculizumab, ravulizumab, inebilizumab and satralizumab.

Keywords: neuromyelitis optica spectrum disorders (NMOSD), aquaporin-4 (AQP4) antibodies, immunotherapies, long­‑term management.

Received: April 10, 2024; Revised: April 10, 2024; Accepted: April 15, 2024; Prepublished online: April 15, 2024; Published: June 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Szilasiová J. New treatment options for Neuromyelitis optica spectrum disorders (NMOSD). Neurol. praxi. 2024;25(3):224-229. doi: 10.36290/neu.2024.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long­‑term effects. Mult Scler Relat Disord. 2020;46:102538. Go to original source... Go to PubMed...
    2. Costello F, Burton JM. Contemporary management challenges in seropositive NMOSD. J Neurol. 2022:1-8. Go to original source... Go to PubMed...
    3. Cree BA, Lamb S, Morgan K, Chen A, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64:1270-1272. Go to original source... Go to PubMed...
    4. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N­‑MOmentum): a double­‑blind, randomised placebo­‑controlled phase 2/3 trial. The Lancet. 2019;394:1352-1363. Go to original source... Go to PubMed...
    5. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta­‑analysis. JAMA Neurol. 2016;73:1342-1348. Go to original source... Go to PubMed...
    6. Giovannelli J, Ciron J, Cohen M, et al. A meta­‑analysis comparing first­‑line immunosuppressants in neuromyelitis optica. Ann Clin Transl Neurol. 2021;8:2025-2037. Go to original source... Go to PubMed...
    7. Kim W and Kim HJ. An update on biologic treatments for neuromyelitis optica spectrum disorder. Expert Rev Clin Immunol. 2023;19(1):111-121. Go to original source... Go to PubMed...
    8. Kümpfel T, Giglhuber K, Aktas O, et al. The Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long‑term management. Journal of Neurology. 2023;271(1):141-176. Go to original source... Go to PubMed...
    9. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol. 2016;79:206-216. Go to original source... Go to PubMed...
    10. Li R, Li C, Huang Q, et al. Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation. Eur J Neurol. 2022;29:2792-2800. Go to original source... Go to PubMed...
    11. Lin J, Xue B, Zhu R, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021;42:3857-3863. Go to original source... Go to PubMed...
    12. Nakashima I, Nakahara J, Yokote H, et al. Long­‑term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody­‑positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post­‑marketing surveillance in Japan. Ther Adv Neurol Disord. 2023;16:1-13. Go to original source... Go to PubMed...
    13. Palace J, Wingerchuk DM, Fujihara K, et al. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021;47:102641. Go to original source... Go to PubMed...
    14. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93:1053-1068. Go to original source... Go to PubMed...
    15. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614-625. Go to original source... Go to PubMed...
    16. Rensel M, Zabeti A, Mealy MA, et al. Long­‑term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G­‑seropositive participants taking inebilizumab for ≥ 4 years in the N­‑MOmentum trial. Mult Scler (Houndmills, Basingstoke, Engl). 2022;28:925-932. Go to original source... Go to PubMed...
    17. Ringelstein M. ECTRIMS 2022 - ePoster. Mult Scler J. 2022;28:692-945. Go to original source...
    18. Ringelstein M, Ayzenberg I, Harmel J, et al. Long­‑term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72:756-763. Go to original source... Go to PubMed...
    19. Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta­‑analysis. J Neurol. 2021;268:4549-4562. Go to original source... Go to PubMed...
    20. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double­‑blind, placebo­‑controlled trial. Lancet Neurol. 2020;19:298-306. Go to original source... Go to PubMed...
    21. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double­‑blind, multicentre, placebo­‑controlled phase 3 trial. Lancet Neurol. 2020;19:402-412. Go to original source... Go to PubMed...
    22. Valencia­‑Sanchez C, Wingerchuk DM. Emerging targeted therapies for Neuromyelitis Optica Spectrum Disorders. BioDrugs. 2021;35:7-17. Go to original source... Go to PubMed...
    23. Wang Y, Zhong X, Wang H, et al. Batoclimab as an add­‑on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2022;30:195-203. Go to original source... Go to PubMed...
    24. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-189. Go to original source... Go to PubMed...
    25. Wingerchuk DM, Fujihara K, Palace J, et al. Long­‑term safety and efficacy of eculizumab in aquaporin-4 IgG positive NMOSD. Ann Neurol. 2021;89:1088-1098. Go to original source... Go to PubMed...
    26. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114-2124. Go to original source... Go to PubMed...
    27. Yamamura T, Weinshenker B, Yeaman MR, et al. Long­‑term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. Go to original source... Go to PubMed...
    28. Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open­‑label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391-401. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.